Hexanoylcarnitine
|
Basic information |
| Metabolite name | Hexanoylcarnitine |
 | HMDB0000756 |
 |
N/A |
 |
3246938 |
| Synonyms | carnitine C6:0; |
| No. of studies | 9 |
|
Basic information |
| Metabolite name | Hexanoylcarnitine |
| HMDB0000756 |
|
N/A |
|
3246938 |
| Synonyms | carnitine C6:0; |
| No. of studies | 9 |
|
Relationship between Hexanoylcarnitine and depression (count: 9) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M061 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M1021 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1099 | Type2 | chronic social isolation + fluoxetine group vs. chronic social isolation group | Prefrontal cortex | Wistar rat | Down |
| Study M1140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Nucleus accumbens | C57BL/6 J mouse | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Down |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Up |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |